Bolivia Medical Device Premarket Pathway: End-to-End Registration Process
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The premarket pathway for medical devices in Bolivia is a four-step sequence: pay the official service fee and obtain the payment receipt, submit the registration dossier, complete the AGEMED technical review, and obtain the sanitary registration. The decisive structural feature is payment before submission. Chapter 3 of the Manual para Registro Sanitario de Dispositivos Médicos places the payment of the service fee and the issuance of the payment receipt ahead of dossier submission, and the applicable fee schedule is governed by Resolución Ministerial N° 0265, dated May 25, 2018. Review outcomes take one of three forms: approval (APROBADO, with the registration recorded as issued, EMITIDO), observation (OBSERVADO), or rejection (RECHAZADO). GRZAN assesses that scheduling payment after submission is a procedural error: because the payment receipt is a formal component of the dossier, an application filed without it will not be accepted for processing at all.
AGEMED (Agencia Nacional de Medicamentos y Tecnologías en Salud) administers this pathway as the single national authority for the sanitary registration of medical devices, and the four steps apply equally to imported and locally supplied products. In practice the sequence behaves like a strict queue: the file enters technical review only after the payment receipt has been generated and the dossier has passed the completeness check described in Chapter 3 of the manual. For imported devices the importer of record holds the registration, which means the fee payment, the submission, and all correspondence with AGEMED run through the Bolivian importer or its authorized representative. Companies exporting to Bolivian distributors should therefore treat pathway design — who pays, who files, who answers observations — as a commercial decision to be fixed in the distribution agreement before any document is prepared.
2. Legal basis
| Regulation | Reference | Publication date | Provision |
|---|---|---|---|
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version published on the AGEMED website | Chapter 3 |
| Resolución Ministerial (fees and procedures) | Resolución Ministerial N° 0265 | May 25, 2018 | Full text |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version published on the AGEMED website | Section 3.1.5 |
| Ley del Medicamento (Pharmaceuticals Law) | Ley N° 1737 | December 17, 1996 | Article 2 |
Read together, these instruments define the regulatory spine of a Bolivian device application. Ley N° 1737 establishes the sanitary registration obligation for health products placed on the national market; the manual issued under Resolución Ministerial N° 010 sets out the dossier content, the grouping rules, and the review sequence in Chapter 3; and Resolución Ministerial N° 0265 fixes the fees and procedural parameters that make the payment step the formal opening act of the file. Because the manual is maintained as a living document, applicants must verify the version currently in force on the AGEMED website before compiling the dossier.
3. Expert insights
Insight 1: the payment receipt is part of the dossier, not a financial by-product. Chapter 3 of the manual lists obtaining the payment receipt as a formal step, which means the applicant must be able to produce proof of payment at the moment of submission. Companies planning budgets and foreign-exchange arrangements must therefore place this official fee ahead of document preparation, not after it. Bolivia’s foreign-exchange and payment channels are themselves part of the lead time: cross-border transfers to a Bolivian public account can require banking arrangements that take measurable time to establish, and the receipt can only be generated once the funds have cleared under the fee schedule of Resolución Ministerial N° 0265.
Insight 2: the three outcomes lead to three different paths with very different costs. Approval moves the file into certificate issuance and printing. Observation opens a 60 calendar day window to respond, during which the review is suspended rather than restarted. Rejection, by contrast, requires a new payment and a new submission, which means the process is effectively walked a second time from the beginning. The three outcomes are therefore not a distinction of speed but a distinction of whether the official fee must be paid again — a difference that can double the regulatory cost of a single product.
Insight 3: virtual procedure and physical verification run in parallel. Bolivia’s official procedure catalogue lists the registration of imported devices as a virtual procedure, with documents uploaded through the AGEMED platform. The technical review stage, however, can still require physical verification, including the warehouse inspection contemplated in Section 2.6 of the manual. Digital submission therefore does not mean paperless compliance: importers must maintain storage premises in Bolivia that can pass an on-site check at any time during the review window and after the registration has been granted.
4. Practical recommendations
- Place the official fee payment at the first node of the critical path, and reserve time for the foreign-exchange and banking arrangements that precede it.
- Budget on the assumption of at least one observation round, writing the possibility of a second payment into the budget assumptions from day one.
- Start label and packaging preparation immediately after submission, so that certificate issuance is not followed by a packaging rework that delays the market launch.
These three measures share one logic: every step that can run in parallel with the official review should run in parallel. The review clock belongs to AGEMED; the preparation of labels, import logistics, and warehouse readiness belongs to the applicant. Companies that treat the official review window as idle waiting time routinely lose additional months after approval, precisely because printing, labelling, and import readiness steps were never started while the file was still under review.
A final observation concerns sequencing discipline inside the four steps. Because the payment receipt is generated against the specific application, companies should not pay before the dossier is genuinely ready: paying early buys no advantage and starts no clock, while paying late blocks the submission entirely. The practical optimum is to reach document readiness first, arrange the transfer second, and submit within days of receiving the receipt. Teams that follow this order convert the payment-before-submission rule from an obstacle into a simple scheduling constraint, and they avoid the most expensive scenario in this pathway — a file that has been paid for but cannot yet be filed.
5. Verification checklist
- □ Confirm the payment receipt has been obtained and included in the dossier
- □ Confirm the fee has been calculated under the current text of Resolución Ministerial N° 0265
- □ Confirm the dossier has been uploaded through the AGEMED virtual procedure entry point
- □ Confirm a contingency plan for an OBSERVADO outcome is in place
- □ Confirm the warehouse can accept a physical inspection at any time
GRZAN registration support. GRZAN provides end-to-end medical device registration support in Bolivia for manufacturers, importers, and authorized representatives, covering fee planning, dossier preparation, submission through the AGEMED virtual procedure, and responses throughout the technical review. For project inquiries, contact info@grzanglobal.com.
Regulatory information verified as of October 29, 2026.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us